BeOne Medicines revenue jumps 30% to $1.7 billion

• BeOne Medicines’ second-quarter revenue increased 30% to $1.705 billion, while GAAP net income reached $237 million.
• BRUKINSA revenue rose 31% to $1.2 billion, including $893 million generated in the United States.
• BeOne raised its 2026 revenue guidance to $6.6–$6.8 billion and increased its operating-income forecasts.

BeOne Medicines (NASDAQ:ONC) reported second-quarter revenue of $1.705 billion, up 30%, as BRUKINSA sales expanded globally.

Revenue rose from $1.315 billion a year earlier, while BRUKINSA revenue increased 31% to $1.2 billion, including $893 million in U.S. sales.

GAAP operating income reached $325 million, net income was $237 million, and free cash flow nearly doubled to $435 million.

BeOne raised 2026 revenue guidance to $6.6–$6.8 billion.

BRUKINSA generated $1.2 billion, TEVIMBRA produced $229 million, and Amgen in-licensed products contributed $157 million during the quarter.

BeOne recently expanded its New Jersey manufacturing site, secured U.S. approval for BEQALZI and advanced several late-stage oncology studies.